• 中文版
  • Home
  • About Us
    • Contract Research Organization
    • Contract Development and Manufacturing Organization
    • Accolades
    • Publications
  • Services Overview
  • Discovery Chemistry
    • Synthetic Chemistry
    • Medicinal Chemistry
    • Library Chemistry
    • Peptide Chemistry
    • Fragment Based Screening
    • Computer Aided Drug Design
    • Analytical Services
    • Protein Structure
  • Biology & Pharmacology
    • Oncology
    • Pathology Core Facility
    • Immunology
    • Tumor Immunology
    • Neuroscience
    • Cell Biology
    • In Vitro Biology
      • Kinases
      • Epigenetics
      • GPCR, NR, Ion-channel, Transporter
      • Ubiquitin & PROTAC
      • KRAS
      • COVID-19
      • Radiometric
      • Customized assay development
      • High throughput screening
      • MOA Study
    • Metabolic & Cardiovascular Diseases
  • DMPK / Exploratory Toxicology
    • DMPK / Exploratory Toxicology
    • Biomarkers, Preclinical & Clinical Sample Bioanalysis
    • Large molecule PK/BA services
  • Biologics Discovery
    • Antibody Discovery
    • Protein Science
    • Biologics Analytical Services
    • B Cell Cloning
  • Biologics CMC
    • Stable Cell Line Development
    • Process Development
    • Formulation Development
    • Aseptic Filling and Freeze-drying
    • Drug Developability / Manufacturability study
    • Final Container Extractables & Leachables Study
    • Analytical Development and Testing
    • GMP Production
  • Small Molecule CMC
    • Process R&D Services
    • Process Safety
    • Analytical Development
    • Pre-Formulation Development
    • Formulation Development
    • ICH Stability Studies
    • CMC CTD Support
    • Manufacturing
  • Blog
  • Careers
  • News & Events
    • Webinars
  • Contact Us
  • Download Center

Call us today! +86 21 5132 0088

contact@chempartner.com
中文版
Shanghai ChemPartner Shanghai ChemPartner Shanghai ChemPartnerShanghai ChemPartner
  • Home
  • About Us
    • About ChemPartner
    • CRO
    • CDMO
    • Accolades
    • Publications
  • Services
    • Discovery Chemistry
      • Synthetic Chemistry
      • Medicinal Chemistry
      • Library Chemistry
      • Peptide Chemistry
      • Fragment Based Screening
      • Computer Aided Drug Design
      • Analytical Services
      • Protein Structure
    • Biology & Pharmacology
      • Oncology
      • Pathology Core Facility
      • Immunology
      • Tumor Immunology
      • Cell Biology
      • In Vitro Biology
      • Neuroscience
      • Metabolic & Cardiovascular Diseases
      • Epigenetics
    • DMPK / Exploratory Toxicology
      • DMPK / Exploratory Toxicology
      • Biomarkers, Preclinical & Clinical Sample Bioanalysis
      • Large molecule PK/BA services
    • Biologics Discovery
      • Antibody Discovery
      • Protein Science
      • Biologics Analytical Services
      • B Cell Cloning
    • Biologics CMC
      • Stable Cell Line Development
      • Process Development
      • Formulation Development
      • Aseptic Filling and Freeze-drying
      • Drug Developability / Manufacturability study
      • Final Container Extractables & Leachables Study
      • Analytical Development and Testing
      • GMP Production
    • Small Molecule CMC
      • Process R&D Services
      • Process Safety
      • Analytical Development
      • Pre-Formulation Development
      • Formulation Development
      • ICH Stability Studies
      • CMC CTD Support
      • Manufacturing
  • Blog
  • Careers
  • News & Events
    • Webinars
  • Contact Us
  • Download Center

Dr. Lilly Xu joins ChemPartner as Vice President and Head of DMPK and Exploratory Toxicology

Jun 28, 2017 | Press Release |

Shanghai, China (June 28, 2017) – Shanghai ChemPartner today announced the appointment of Lilly Xu, Ph.D. as Vice President and the Head of DMPK and Exploratory Toxicology at the company headquarters in Shanghai, China.

Dr. Xu has more than 20 years of experience in the area of drug metabolism, pharmacokinetics and toxicology. She was one of the pioneers in developing cultured human hepatocytes as a tool to study metabolism of xenobiotics and induction of P450 isozymes. Prior to joining ChemPartner, Dr. Xu was the Head of the Center of Predictive ADMET at Sanofi/Icagen. She received her Ph.D. in Cell and Molecular Biology from Saint Louis University.

Since the DMPK and Exploratory Toxicology department’s inception in 2006, it has been one of the most rapidly growing business units in the company. This growth is a testament to the high-quality performance and experienced leadership by the scientific team.

“ DMPK is important to Chempartner and our biopharmaceutical clients with respect to drug discovery and development to meet unmet medical needs. We needed an experienced leader to maintain the quality of service that keep our clients satisfied and coming back. Dr. Xu’s expertise, knowledge, and dedication make her a great fit for the team,” said Dr. Wei Tang, President of ChemPartner. Dr. Tang previously served as Senior Vice President, Biology, Biologics, and DMPK and hired Dr. Xu to lead the talented team.

“ChemPartner’s DMPK Exploratory Toxicology integrated service, working in unison with our Chemistry, Biologics, and Biology departments, is the best model for helping our clients to deliver their hits, leads, and candidates in a fast and high quality manner. Our goal at ChemPartner has always been to deliver high quality data to our clients and provide scientific interpretation of the data, thereby helping to solve problems through our expertise in DMPK and toxicology,” said Dr. Xu.

ChemPartner’s DMPK and Exploratory Toxicology department consists of bioanalytical (small and large molecules, discovery, and regulated), in vitro ADME, in vivo pharmacokinetics, and toxicology (non-GLP and partnered GLP) groups. Working closely with Chemistry, Biology/Pharmacology, and Biologics, the department supports translational medicine with experience in formulation development, in vitro and in vivo PK extrapolation, PK/PD correlation, and biomarker analysis including metabolomics.

About ChemPartner
Shanghai ChemPartner is a full-service life science CRO with over 15 years of pharmaceutical research experience. With a team of over 2000 experienced scientists, hundreds of western-trained pharmaceutical industry leaders, and experienced pharmaceutical executive leadership at the helm, ChemPartner is aligned and dedicated to technically and strategically accomplishing the research initiatives of pharma and biotech companies worldwide.

—
FOR MORE INFORMATION
Livia Legg, MS, Chief Commercial Officer
news@chempartner.com

Tags: ChemPartnerDMPKExploratory Toxicology
0
Share

You also might be interested in

ChemPartner Announces its Expansion into Peptide Chemistry

ChemPartner Announces its Expansion into Peptide Chemistry

Jan 8, 2016

ShangPharma inks an Important Collaboration with Investment in Circle Pharma[...]

San Diego, April 5-9, 2014, ChemPartner attended AACR.

San Diego, April 5-9, 2014, ChemPartner attended AACR.

Apr 26, 2016

The American Association for Cancer Research 2016 Annual Meeting,as one[...]

ChemPartner at the 18th Shanghai International Froum on Biotechnology & Pharmaceutical Industry

ChemPartner at the 18th Shanghai International Froum on Biotechnology & Pharmaceutical Industry

Jun 22, 2016

The 18th International Forum on Biotechnology & Pharmaceutical Industry (Bio-Forum)[...]

Latest News

ChemPartner Makes Additional Investments in Biologics from Research to Manufacturing Capabilities

06/11/2020

Shanghai, China (June 9, 2020) – Shanghai ChemPartner...

ChemPartner Assists the Mount Sinai Health System in Producing Reagent for COVID-19 Research

05/12/2020

Shanghai, China (May 12, 2020) – Shanghai ChemPartner...

ChemPartner and the Gladstone Institutes Announce COVID-19 Research Collaboration

04/17/2020

SAN FRANCISCO, Calif. and SHANGHAI, China. (April 15, 2020)...

ChemPartner Introduces New State-of-the-Art Global Operation Center in Shanghai

04/02/2020

Shanghai, China (March 17, 2020) – Shanghai ChemPartner...

Dr. Jie Jack Li joins Shanghai ChemPartner as a Vice President of Discovery Chemistry

12/18/2019

Shanghai, China (December 17, 2019) – Shanghai ChemPartner...

Shanghai ChemPartner was awarded “TOP 10 CMOs in 2019”

Shanghai ChemPartner was awarded “TOP 10 CMOs in 2019”

07/19/2019

Contract manufacturers play a significant role when it comes...

Tag Cloud

2017 AACR Agreement Antibody Engineering art Berkeley Lights Best Life Science BIOtech Blend Boston Capital Market Chemistry ChemPartner Congratulates CPhI CPSA Shanghai 2016 CRO DMPK Exploratory Toxicology Labs layout Merger Deal PEGS PEGS CHINA Peptide Pharma Pharmacology product PTF Qidong Quantum Hi-Tech China Biological Research Facility San Diego San Francisco Shanghai Shanghai ChemPartner ShangPharma Sponsor Strategic Corporate Restructuring Tarveda Therapeutic Top 10 CMOs Vice President World ADC

Give us a Message

You can leave us a message by quick contact box and we'll get back to you, asap. Thanks!

Send Message

Logo

ChemPartner is a leading research organization providing high-quality and cost-effective services for the pharmaceutical and biotechnology industry.

Get started today.

Contact Us
  • Shanghai ChemPartner Co., Ltd.
  • 1F & 3F, Block A, 2829 JinKe Road, Zhangjiang Hi-Tech Park, PuDong New Area, Shanghai China, 201203
  • +86 21 5132 0088
  • contact@chempartner.com

© 2021 — Shanghai ChemPartner Co., Ltd. All Rights Reserved  About Us  Careers  Contact Us  Privacy Policy  Sitemap

  • Home
  • Contact
  • Buy Highend
Prev Next